Efficacy and toxicity of IFN-α2b combined with cytarabine in chronic myelogenous leukaemia
- 1 September 1999
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 106 (4), 1013-1019
- https://doi.org/10.1046/j.1365-2141.1999.01662.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid LeukemiaNew England Journal of Medicine, 1998
- Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1997
- Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: Results of the austrian multicenter phase II studyLeukemia Research, 1997
- Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α TherapyAnnals of Internal Medicine, 1995
- Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1994
- Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabineAmerican Journal of Hematology, 1993
- Cytogenetic Remissions in Chronic Myelogenous Leukemia Using Interferon Alpha-2a and Hydroxyurea with or without Low-Dose Cytosine ArabinosideLeukemia & Lymphoma, 1991
- Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemiaLeukemia Research, 1988
- Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemiaCancer, 1987
- Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1986